Elsevier

Bioorganic & Medicinal Chemistry

Volume 22, Issue 22, 15 November 2014, Pages 6459-6470
Bioorganic & Medicinal Chemistry

2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion

https://doi.org/10.1016/j.bmc.2014.09.036Get rights and content
Under a Creative Commons license
open access

Abstract

A novel series of 8-amino imidazo[1,2-a]pyrazine derivatives has been developed as inhibitors of the VirB11 ATPase HP0525, a key component of the bacterial type IV secretion system. A flexible synthetic route to both 2- and 3-aryl substituted regioisomers has been developed. The resulting series of imidazo[1,2-a]pyrazines has been used to probe the structure–activity relationships of these inhibitors, which show potential as antibacterial agents.

Keywords

8-Amino imidazo[1,2-a]pyrazine
Bacterial type IV secretion system
HP0525
ATPase inhibitor

Cited by (0)

Present address: MedPharm Ltd, R&D Centre, Unit 3/Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford GU2 7AB, UK.

Present address: Dept. Cell and Molecular Biology, Karolinska Institutet, Berzelius väg 35, SE-171 77 Stockholm, Sweden.

§

Present address: Redx Oncology Ltd, Duncan Building, Royal Liverpool University Hospital, Crown Street, Liverpool L69 3GA, UK.

Present address: Leiden Institute of Chemistry, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, Netherlands.

Present address: The EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK.

††

Present address: Department of Theoretical and Computational Biophysics, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, D-37077 Göttingen, Germany.

‡‡

Present address: NewSouth Innovations Pty Limited, Rupert Myers Building, UNSW, Sydney, NSW 2052, Australia.